(1996) published the Phase I clinical study of MT-II demonstrating melanotropic activity (PMID 8637402)
Research published in Scientific Reports demonstrates that aged mice treated with NNMT inhibitors showed approximately 40% greater grip strength compared to untreated controls, remarkably surpassing even the benefits achieved through intensive exercise alone, which produced only 20% improvement
MOTS-C represents a distinct category among the best peptides for weight loss research as a mitochondrial-derived peptide (MDP) encoded within the 12S rRNA region of the mitochondrial genome, first identified as a regulator of metabolic homeostasis by Lee and colleagues
The peptide is not FDA-approved for any medical condition and is typically used as a research compound or through compounding pharmacies
The panel that voted on these peptides included several members with ties to the peptide industry, and some voted explicitly citing "medical freedom" rather than clinical evidence
Brand-name GLP-1 medications cost $900 to $1,500 monthly without insurance coverage
